Investors Focus on Fortune-Making Immuno-Oncology Race

On Tuesday's edition of Market Checkup, Motley Fool health-care analyst David Williamson looks at the biggest winners and losers in health-care stocks today.

Bristol-Myers Squibb (NYSE: BMY  ) took a hit recently, when it was unclear about its timeline for advancing its lead immuno-oncology drug candidate Nivolumab. While investors are excited about how this may pair up with Bristol's already approved drug Yervoy, management is taking a cautious pace while it tests out a number of different drug pairings. This delay has not only put doubt about the pairing in the mind of investors, but it has also given Merck (NYSE: MRK  ) , which has a similar drug in development that would be a direct competitor, a chance to strike.

In this segment, David breaks this competitive race down for investors and discusses what to watch with these two companies in this space.

So what's the best way for investors to play the biotech space today?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2813926, ~/Articles/ArticleHandler.aspx, 8/28/2015 11:12:06 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated Moments ago Sponsored by:
DOW 16,593.30 -61.47 -0.37%
S&P 500 1,984.14 -3.52 -0.18%
NASD 4,807.49 -5.21 -0.11%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 10:56 AM
BMY $60.71 Down -0.11 -0.18%
Bristol-Myers Squi… CAPS Rating: ****
MRK $55.05 Up +0.10 +0.18%
Merck & Co., Inc. CAPS Rating: ****